Monthly Archives: June 2012
By Guest Blogger | Published: June 17, 2012
Final: THE COST OF PHARMA DIVORCE Corporate spin-offs are on the rise across the pharmaceutical sector, but at what cost to shareholders? Brian McGilligan, AVP, Life Sciences Program Management Consulting Lead at Cognizant argues that in haste to obtain decree absolute, demerging businesses could be threatening their long term viability. Demergers are in fashion again. […]
By Ben Comer | Published: June 15, 2012
A diverse group of HIT professionals – including physicians, academics, developers and entrepreneurs – gathered at Sudler & Hennessey’s Health and Technology Summit in New York City to discuss the challenges related to health information technology implementation, and the ways to move forward.
By admin | Published: June 11, 2012
A new study suggests that physicians who see fewer reps are slower when it comes to dropping ‘black-box’ drugs—and at adopting promising new medications. If you’ve ever had any doubts about whether your sales reps are actually affecting the prescribing habits of the physicians they visit, a new report by ZS Associates, recently reported on […]
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By William Looney | Published: June 11, 2012
Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV. More important, multidrug resistant TB is now found in […]